Colon Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colon Cancer, including details on causes, treatment, symptoms.

Correlates and outcomes of tumor adherence in resected colonic and rectal cancers.

Darakhshan A, Lin BP, Chan C, Chapuis PH, Dent OF, Bokey L

Concord Hospital, Sydney, Australia.

OBJECTIVES: The aims of this study were to examine the associations between tumor adherence and other operative findings, postoperative complications, recurrence, and survival after resection of colorectal cancer. SUMMARY BACKGROUND DATA: The prognostic importance of tumor adherence to other organs or structures, either by direct invasion (T4) or simply by inflammatory adhesions, is yet to be clearly defined as earlier studies have been limited in size or have not used contemporary multivariable statistical techniques. METHODS: Data were drawn from a comprehensive, prospective hospital registry of all resections for colorectal cancer between January 1971 and December 2000 with follow-up to December 2005. Statistical analysis employed the chi test, Kaplan-Meier estimation, and proportional hazards regression with a significance level of <0.05 and 95% confidence intervals (CI). RESULTS: Tumor adherence was identified in 268 of 2504 resections (10.7%). Adherent tumors were more likely than nonadherent tumors to be spontaneously or surgically perforated or transected, to have nodal metastases and to be poorly differentiated. Venous invasion was more frequent in adherent colonic but not rectal tumors. Adherence was associated with only 5 of 16 medical and surgical complications considered. In rectal cancer, adherence was independently associated with pelvic recurrence (hazard ratio 1.8, 95% CI 1.2-2.7) and diminished survival (hazard ratio 1.6, 95% CI 1.3-2.0) after adjustment for other variables. CONCLUSION: In rectal cancer, tumor adherence indicates a poor prognosis after adjustment for other prognostic factors, regardless of whether actual tumor invasion of the adherent structure has occurred. However, adherence is not associated with survival after resection of colonic cancer.

Published 24 April 2008 in Ann Surg, 247(4): 650-8.
Full-text of this article is available online (may require subscription).

Articles on Colon Cancer published 15 April 2008:

Not all acute lower back pain is benign--paravertebral abscess and colonic cancer.   Am J Emerg Med, 26(4): 513.e3-4.

Low back pain with sciatica is one of the most common complaints of patients presenting to the ED, and it is usually managed on an outpatient basis. However, acute lower back pain not always derives from a benign cause. We report here the case of a 63-year-old diabetic man who presented to the ED complaining of acute low back pain with sciatica and fever. The cause was a large paravertebral abscess by Streptococcus milleri, and this was the first presenting sign of an unknown underlying colonic ... [Abstract] [Full-text]

Articles on Colon Cancer published 11 April 2008:

Progress and challenges in the adjuvant treatment of stage II and III colon cancers.   Expert Rev Anticancer Ther, 8(4): 595-604.

Whereas the benefit of adjuvant 5-fluorouracil and leucovorin have been well established in resected stage III colon cancer, a significant benefit for patients with stage II disease has been more difficult to demonstrate. More recently, oxaliplatin-based chemotherapy with regimens such as oxaplatin plus 5-fluorouracil/leucovorin have been shown to improve disease-free and overall survival in these stage III patients. This review will discuss the development of adjuvant chemotherapy in colon ... [Abstract] [Full-text]

Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.   Expert Rev Anticancer Ther, 8(4): 547-51.

The current standard adjuvant chemotherapy for suitable patients with stage III colon cancer is the combination of oxaliplatin and 5-fluorouracil plus folinic acid (5-FU/LV). However, until recently and for many years prior to this, the accepted standard adjuvant chemotherapy was 6-8 months of bolus 5-FU/LV. However, bolus treatment was associated with significant toxicity, namely stomatitis, diarrhea and neutropenia, in addition to multiple hospital visits for drug administration for patients. ... [Abstract] [Full-text]

Articles on Colon Cancer published 10 April 2008:

p53 regulates FAK expression in human tumor cells.   Mol Carcinog, 47(5): 373-82.

Attenuation of the p53 protein is one of the most common abnormalities in human tumors. Another important marker of tumorigenesis is focal adhesion kinase (FAK), a 125-kDa tyrosine kinase that is overexpressed at the mRNA and protein levels in a variety of human tumors. FAK is a critical regulator of adhesion, motility, metastasis, and survival signaling. We have characterized the FAK promoter and demonstrated that p53 can inhibit the FAK promoter activity in vitro. In the present study, we ... [Abstract] [Full-text]

Human APC sequesters beta-catenin even in the absence of GSK-3beta in a Drosophila model.   Oncogene, 27(17): 2488-93.

There have been conflicting reports on the requirement of GSK-3beta-mediated phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) vis-à-vis its ability to bind and degrade beta-catenin. Using a unique combination of loss of function for Shaggy/GSK-3beta and a gain of function for human APC in Drosophila, we show that misexpressed human APC (hAPC) can still sequester Armadillo/beta-catenin. In addition, human APC could suppress gain of Wnt/Wingless phenotypes associated with ... [Abstract] [Full-text]

Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC).   Mol Carcinog, 47(5): 321-5.

Phenethyl isothiocyanate (PEITC) is an isothiocyanate which is a major constituent of watercress and other cruciferous vegetables. Its chemopreventive potential has been previously shown in various rodent models of cancer. In this study, we investigated the chemopreventive efficacy of PEITC in the Apc(Min/+) mouse model. Apc(Min/+) mice were fed with diet supplemented with 0.05% of PEITC for 3-wk. Our results clearly demonstrated that Apc(Min/+) mice fed with PEITC supplemented diet developed ... [Abstract] [Full-text]

Articles on Colon Cancer published 8 April 2008:

Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy.   Nat Med, 14(4): 454-8.

A combination of targeted probes and new imaging technologies provides a powerful set of tools with the potential to improve the early detection of cancer. To develop a probe for detecting colon cancer, we screened phage display peptide libraries against fresh human colonic adenomas for high-affinity ligands with preferential binding to premalignant tissue. We identified a specific heptapeptide sequence, VRPMPLQ, which we synthesized, conjugated with fluorescein and tested in patients ... [Abstract] [Full-text]

Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum.   Semin Oncol, 35(2): 183-91.

Peritoneal carcinomatosis (the implantation of tumor cells throughout the peritoneal cavity) occurs in as many as 50% of patients with colorectal cancer and in up to 25% is the only site of recurrence. There is increasing evidence that aggressive debulking of peritoneal only disease followed by intraperitoneal chemotherapy can have significant impact on the patient's quality and sometimes quantity of life. This chapter will provide an overview of the biologic basis of pathogenesis and the ... [Abstract] [Full-text]

© 2004-2008 Colon Cancer Research Today. All Rights Reserved.